CD8+ T cells retain protective functions despite sustained inhibitory receptor expression during Epstein-Barr virus infection in vivo.
Adult
Animals
CD8-Positive T-Lymphocytes
/ immunology
Case-Control Studies
Cytokines
/ metabolism
Epstein-Barr Virus Infections
/ immunology
Gene Expression Profiling
Herpesvirus 4, Human
/ immunology
Humans
Inflammation Mediators
/ metabolism
Mice
Mice, Inbred NOD
Mice, SCID
Programmed Cell Death 1 Receptor
/ metabolism
T-Lymphocytes, Cytotoxic
/ immunology
Viral Load
/ immunology
Journal
PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
received:
27
11
2018
accepted:
04
04
2019
entrez:
31
5
2019
pubmed:
31
5
2019
medline:
8
11
2019
Statut:
epublish
Résumé
Epstein Barr virus (EBV) is one of the most ubiquitous human pathogens in the world, persistently infecting more than 90% of the adult human population. It drives some of the strongest human CD8+ T cell responses, which can be observed during symptomatic primary infection known as infectious mononucleosis (IM). Despite high viral loads and prolonged CD8+ T cell stimulation during IM, EBV enters latency and is under lifelong immune control in most individuals that experience this disease. We investigated whether changes in T cell function, as frequently characterized by PD-1 up-regulation, occur during IM due to the prolonged exposure to high antigen levels. We readily detected the expansion of PD-1 positive CD8+ T cells together with high frequencies of Tim-3, 2B4, and KLRG1 expression during IM and in mice with reconstituted human immune system components (huNSG mice) that had been infected with a high dose of EBV. These PD-1 positive CD8+ T cells, however, retained proliferation, cytokine production, and cytotoxic abilities. Multiple subsets of CD8+ T cells expanded during EBV infection, including PD-1+Tim-3+KLRG1+ cells that express CXCR5 and TCF-1 germinal center homing and memory markers, and may also contain BATF3. Moreover, blocking the PD-1 axis compromised EBV specific immune control and resulted in virus-associated lymphomagenesis. Finally, PD-1+, Tim-3+, and KLRG1+ CD8+ T cell expansion coincided with declining viral loads during low dose EBV infection. These findings suggest that EBV infection primes PD-1 positive CD8+ T cell populations that rely on this receptor axis for the efficient immune control of this ubiquitous human tumor virus.
Identifiants
pubmed: 31145756
doi: 10.1371/journal.ppat.1007748
pii: PPATHOGENS-D-18-02269
pmc: PMC6542544
doi:
Substances chimiques
Cytokines
0
Inflammation Mediators
0
Programmed Cell Death 1 Receptor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1007748Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Nature. 2012 Oct 25;490(7421):502-7
pubmed: 22992524
Annu Rev Pathol. 2014;9:349-72
pubmed: 24111911
J Immunol. 1987 Dec 1;139(11):3802-7
pubmed: 3119718
N Engl J Med. 2018 May 17;378(20):1947-1948
pubmed: 29768155
J Infect Dis. 2005 Mar 15;191(6):985-9
pubmed: 15717276
N Engl J Med. 2010 May 27;362(21):1993-2000
pubmed: 20505178
J Infect Dis. 2005 Nov 1;192(9):1505-12
pubmed: 16206064
Annu Rev Immunol. 2007;25:587-617
pubmed: 17378764
Nat Immunol. 2008 Oct;9(10):1091-4
pubmed: 18800157
J Exp Med. 2012 Mar 12;209(3):471-8
pubmed: 22393125
J Clin Invest. 2015 Jan;125(1):304-15
pubmed: 25485679
Immunity. 2018 May 15;48(5):1029-1045.e5
pubmed: 29768164
PLoS Pathog. 2015 Dec 01;11(12):e1005286
pubmed: 26624012
Haematologica. 2010 Dec;95(12):2080-7
pubmed: 20823128
Nature. 2006 Feb 9;439(7077):682-7
pubmed: 16382236
Semin Cancer Biol. 2008 Dec;18(6):381-7
pubmed: 18996483
Nat Immunol. 2011 Jun;12(6):492-9
pubmed: 21739672
Eur J Immunol. 2001 Mar;31(3):677-86
pubmed: 11241270
Nat Immunol. 2009 Jan;10(1):29-37
pubmed: 19043418
Cell. 2009 Jul 10;138(1):30-50
pubmed: 19596234
Immunity. 2000 Oct;13(4):497-506
pubmed: 11070168
Proc Natl Acad Sci U S A. 2018 May 1;115(18):4749-4754
pubmed: 29654146
Front Immunol. 2018 Feb 12;9:238
pubmed: 29483919
Bioinformatics. 2011 Jun 15;27(12):1739-40
pubmed: 21546393
J Exp Med. 2015 Jun 29;212(7):1125-37
pubmed: 26034050
J Exp Med. 2009 Jun 8;206(6):1423-34
pubmed: 19487422
PLoS Pathog. 2016 May 17;12(5):e1005642
pubmed: 27186886
J Exp Med. 1998 Dec 21;188(12):2205-13
pubmed: 9858507
Immunity. 2016 May 17;44(5):1052-68
pubmed: 27192569
N Engl J Med. 2003 Oct 2;349(14):1324-32
pubmed: 14523140
J Virol. 2000 Nov;74(21):10249-55
pubmed: 11024158
F1000Res. 2017 May 26;6:748
pubmed: 28663787
N Engl J Med. 1994 Apr 28;330(17):1185-91
pubmed: 8093146
Nat Rev Immunol. 2014 Nov;14(11):768-74
pubmed: 25257362
Arch Neurol. 2007 Jan;64(1):72-5
pubmed: 17210811
J Infect Dis. 2015 Sep 1;212(5):803-7
pubmed: 25722295
Immunity. 2016 Aug 16;45(2):415-27
pubmed: 27533016
Blood. 2004 Feb 15;103(4):1244-52
pubmed: 14576041
Nat Rev Cancer. 2004 Oct;4(10):757-68
pubmed: 15510157
Sci Transl Med. 2019 Jan 16;11(475):
pubmed: 30651320
J Virol. 2005 Jan;79(2):1296-307
pubmed: 15613356
Ann Neurol. 2011 Sep;70(3):515-8
pubmed: 21905083
PLoS Pathog. 2011 Oct;7(10):e1002328
pubmed: 22028659
Immunol Cell Biol. 2011 Mar;89(3):408-16
pubmed: 21301484
Nat Rev Immunol. 2015 Aug;15(8):486-99
pubmed: 26205583
Mech Ageing Dev. 2003 Apr;124(4):477-85
pubmed: 12714256
Annu Rev Pathol. 2006;1:375-404
pubmed: 18039120
Annu Rev Immunol. 2013;31:635-674
pubmed: 23330956
J Virol. 2001 Jun;75(12):5550-8
pubmed: 11356962
N Engl J Med. 1976 Jun 17;294(25):1355-9
pubmed: 177872
J Infect Dis. 2009 Nov 15;200(10):1611-5
pubmed: 19832115
Curr Top Microbiol Immunol. 2015;390(Pt 1):241-65
pubmed: 26424649
Nat Med. 1996 May;2(5):551-5
pubmed: 8616714
Stat Appl Genet Mol Biol. 2004;3:Article3
pubmed: 16646809
J Hepatol. 1999 Mar;30(3):353-8
pubmed: 10190714
Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13022-7
pubmed: 20615947
Curr Opin Virol. 2016 Oct;20:34-39
pubmed: 27591678
Nat Med. 1996 Aug;2(8):906-11
pubmed: 8705861
Oncoimmunology. 2013 Jan 1;2(1):e22590
pubmed: 23483821
Ann Neurol. 2006 Mar;59(3):499-503
pubmed: 16502434
Nucleic Acids Res. 2012 Sep 1;40(17):e133
pubmed: 22638577
Curr Opin Immunol. 2010 Apr;22(2):223-30
pubmed: 20207527